Latest Cost-effectiveness analysis Stories
The American Diabetes Association recommends hemoglobin A1c (HbA1c) testing as one basis for identifying diabetes and prediabetes.
Multiple sclerosis (MS) is an autoimmune disease that affects the brain and spinal cord.
In an era of skyrocketing health-care costs and finite financial resources, health economists are increasingly called upon to determine which medical treatments are the most cost-effective.
In this week's PLoS Medicine, John Ioannidis and Alan Garber from Stanford University, USA, discuss how to use incremental cost-effectiveness ratios (ICER) and related metrics so they can be useful for decision-making at the individual level, whether used by clinicians or individual patients.
Doctors are more apt to recommend a more costly therapy to patients if it were determined to prolong the patient's life rather than just improve quality.
Experts today challenge the view that popular drugs to prevent disease - like statins and antihypertensives to prevent heart disease and stroke, or bisphosphonates to prevent fractures â€“ represent value for money.
OXFORD, England, January 5, 2011 /PRNewswire-FirstCall/ -- Elsevier, the world's leading publisher of scientific, technical and medical information, announced today that it has become the new publisher of the International Society for Pharmacoeconomics and Outcomes Research's (ISPOR) journal Value in Health. Value in Health ( http://www.elsevier.com/wps/find/journaldescription.authors/724501/descriptio n#description) is a multidisciplinary peer-reviewed journal reporting on outcomes...
Neonatal intensive care provides substantial population health benefits in Mexico relative to its costs, even for very premature babies, and as such offers exceptional value for money within the country's Popular Health Insurance (Seguro Popular) program, which offers free access to a specific set of health care interventions.
BOSTON, May 12 /PRNewswire-FirstCall/ -- Experts from PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, will address key trends in late phase development, comparative effectiveness research, cost effective study management, and health outcomes at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting.
- A political dynamiter.